ELMWOOD PARK, N.J.,
Jan. 26, 2021 /PRNewswire/ --
BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ:OPK), today announced COVID-19 testing agreements for
players and officials, as well as team and league staff for the
2020-2021 seasons for the National Basketball Association (NBA) and
National Hockey League (NHL).
BioReference executes COVID-19 testing for NBA, NHL, US National
Soccer Teams, Winter X Games and NBA G League.
For the 2020-21 NBA season, BioReference has been providing
testing services, utilizing PCR and rapid diagnostics, at the 30
NBA team facilities in 28 cities across the U.S. BioReference
previously supported the NBA's 2019-20 season restart.
Under an agreement with the NHL, BioReference will provide
COVID-19 testing to players, coaches, staff and officials, which
includes COVID-19 PCR laboratory-based diagnostics, and rapid
diagnostics to the 24 U.S.-based teams.
In addition, BioReference is currently supporting the Winter X
Games in Aspen, U.S. Soccer's
Women's and Men's National Teams and the NBA G League in
"Continuing to support the NBA in the 2020-21 season, showcases
lessons learned from Orlando, and
leverages emerging technology to support the current season and the
overall partnership we have built throughout the COVID-19
pandemic," said Jon R. Cohen, M.D.,
Executive Chairman of BioReference Laboratories. "Utilizing similar
detailed and systematic protocols, we have been selected to support
the NHL, U.S. Soccer, Winter X Games and NBA G League. It is a
privilege for BioReference to support professional sports,
underscoring our commitment to develop customized solutions that
assist Americans in getting back to the workplace safely and
provide the nation access to entertainment."
About BioReference Laboratories, Inc.
provides comprehensive testing to physicians, clinics, hospitals,
employers, government units, correctional institutions, and medical
groups. BioReference developed and offers test services that yield
high quality and accurate results, including a molecular test for
helping with COVID-19 diagnosis and a serology test to help
indicate possible COVID-19 exposure. The company is in network with
the five largest health plans in the
United States, operates a network of 11 laboratory
locations, and is backed by a medical staff of more than
120 M.D., Ph.D. and other
professional level clinicians and scientists. With a leading
position in the areas of genetics, women's health, maternal fetal
medicine, oncology, and urology, BioReference and its specialty
laboratories, GenPath and GeneDx, are advancing the course of
modern medicine. For more information, visit
About OPKO Health, Inc.
OPKO is a multinational
biopharmaceutical and diagnostics company that seeks to establish
industry-leading positions in large, rapidly growing markets by
leveraging its discovery, development, and commercialization
expertise and novel and proprietary technologies. For more
information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
This press release contains "forward-looking
statements," as that term is defined under the Private Securities
Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
the role and value of testing, whether the results from our
previous testing program can be successfully duplicated or deployed
in other settings or venues, whether implementing the same
strategies or other strategies will be successful in preventing the
spread of the disease or providing safety against infection to the
participants, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business,
technologies and products, and strategies. Many factors could cause
our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements.
These factors include those described in the OPKO Health, Inc.
Annual Reports on Form 10-K filed and to be filed with the
Securities and Exchange Commission and in its other filings with
the Securities and Exchange Commission. In addition,
forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
View original content to download
SOURCE BioReference Laboratories, Inc